Physician profile
Michael S Tehrani
NPI 1427320704
$1,336.95
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $317 · 2023: $406 · 2024: $381 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.19 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $154.14 | 2021-2022 | |
| Novo Nordisk INC | $136.06 | 2024 | Ozempic |
| Alkermes, INC. | $127.76 | 2023-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $122.06 | 2023 | Ingrezza |
| Teleflex LLC | $120.58 | 2023 | Urolift |
| Otsuka America Pharmaceutical, INC. | $117.52 | 2024 | Rexulti |
| Lilly USA, LLC | $114.21 | 2025 | Mounjaro |
| Vanda Pharmaceuticals INC. | $86.59 | 2023-2024 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $38.11 | 2021 | |
| Abbott Laboratories | $27.28 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.06 | 2023 | |
| Sun Pharmaceutical Industries INC. | $22.63 | 2021 | |
| Exact Sciences Corporation | $19.33 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $16.43 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.